December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

153.44 -0.81 (-0.53%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
55 56 Next >
News headline image
The Bad News Heading Into AbbVie's First-Quarter Earnings Report ↗
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically." 
Via Investor's Business Daily
News headline image
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
News headline image
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed. 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years ↗
These income stocks look like good options at current levels. 
Via The Motley Fool
News headline image
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades ↗
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
News headline image
Looking At Novartis's Recent Unusual Options Activity ↗
 
Via Benzinga
Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
1 Magnificent Dividend Stock to Buy and Hold ↗
The company's business went through some important changes last year. 
Via The Motley Fool
News headline image
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%. ↗
Think globally with this high-yielding ETF. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
News headline image
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
News headline image
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday? ↗
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities. 
Via Benzinga
News headline image
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today ↗
SoundHound AI stock is falling on Wednesday as investors in SOUN are worried about the company's plans for a secondary offering. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost ↗
Alibaba stock is up on Wednesday as investors in BABA react to positive comments from cofounder Jack Ma concerning its leadership team. 
Via InvestorPlace
News headline image
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts ↗
Novartis layoffs will see the healthcare company cut 680 jobs in the U.S. and Switzerland over the next two to three years. 
Via InvestorPlace
Topics Workforce
News headline image
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says ↗
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho... 
Via Benzinga
News headline image
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report ↗
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools. 
Via Benzinga
News headline image
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
News headline image
Why Is Novartis Stock Trading Higher On Thursday? ↗
Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile... 
Via Benzinga
News headline image
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch ↗
As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund ↗
Norway's sovereign wealth fund has just five equity investments that represent nearly 13% of its total equity allocation. 
Via Benzinga
News headline image
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
News headline image
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge ↗
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
News headline image
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
News headline image
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
News headline image
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer ↗
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with... 
Via Benzinga
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
News headline image
3 Dividend Stocks to Buy Hand Over Fist in March ↗
Income investors might want to load up on these great dividend stocks. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.